MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1183/13993003.00327-2026

Медицинская библиотека · The European respiratory journal · 2026

Improved Outcomes with Early Aggressive Therapy in Pediatric Pulmonary Hypertension.

Frank Benjamin S, Beghetti Maurice, Berger Rolf M F, Bonnet Damien, Humpl Tilman, Wacker Julie, Douwes Johannes M, Grynblat Julien, Critser Paul J, Bowers David, Ivy D Dunbar, TOPP-2 Investigators

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Pediatric pulmonary arterial hypertension (PAH) carries high mortality with 81% 5-year transplant-free survival. The global Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension-2 (TOPP-2; NCT02610660) registry was created to assess the treatments and outcomes of newly diagnosed pediatric PAH patients. This study evaluates real-world treatment strategies and their relationship with outcomes.

METHODS

Within TOPP-2, 445 subjects with newly diagnosed, catheterization-confirmed WSPH Group 1 pediatric PAH were enrolled. Treatment regimens were classified as none, calcium channel blocker monotherapy, PAH-targeted Monotherapy (Mono), Dual, Triple (enteral/inhaled only), or triple including parenteral prostanoid (TripleX). Baseline treatment strategy was defined as medications received three months following diagnosis. Primary clinical endpoint was death or lung transplantation.

RESULTS

Dual therapy was the most common baseline treatment regimen (40.2%), followed by Monotherapy (29.0%). Phosphodiesterase type 5 inhibitors were the most common class of PAH-targeted therapy (72.4%) followed by endothelin receptor antagonists (59.3%). Adjusting for disease severity at diagnosis, baseline Dual patients had lesser hazard of death/transplant than Mono patients escalating to Dual by year one (HR=0.30, 95% CI=0.16-0.56, p<0.001). Baseline TripleX patients had lesser hazard of death/transplant than those started on enteral/inhaled therapy only and escalated to parenteral by year one (HR=0.28, 95% CI=0.15-0.50, p<0.001).

DISCUSSION: A wide range of pediatric PAH initial medication strategies were observed in the TOPP-2 registry. Therapy regimen escalation within the first year, to Dual for lower-risk patients or to TripleX for higher-risk patients, was associated with worse outcomes compared to those treated more aggressively upfront, supporting upfront over sequential combination therapies.

Для цитирования: Frank Benjamin S, Beghetti Maurice, Berger Rolf M F, Bonnet Damien, Humpl Tilman, Wacker Julie, Douwes Johannes M, Grynblat Julien, Critser Paul J, Bowers David, Ivy D Dunbar, TOPP-2 Investigators. Improved Outcomes with Early Aggressive Therapy in Pediatric Pulmonary Hypertension.. The European respiratory journal. 2026. DOI: 10.1183/13993003.00327-2026.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.